Additionally, the mutation profiles differ, with right-sided tumors more frequently showing BRAF mutations, while left-sided tumors show higher rates of APC and KRAS mutations.5) Moreover, responses to systemic therapy vary based on tumor location. Here, KRAS is linked to neoplasm.